On November 9, 2026 Inocras Inc., a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to deliver curated insights, reported that it will present the first public results from its multimodal agentic AI framework for automating variant curation and clinical interpretation of cancer whole-genome sequencing (WGS) analysis at the Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo, taking place November 10–14 in Seattle.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Developed to address a key scalability bottleneck in clinical Cancer WGS analysis, the AI framework is a preview of Inocras’s CancerVision workflow innovation. In its latest evaluation, the framework achieved 99.5% agreement with expert curation among accepted calls, while deferring 10.2% of candidate variants for expert review. It also demonstrated 98.4% reproducibility across all candidate variants in repeated analyses with identical inputs and settings and is projected to reduce expert review time by more than half.
"Whole-genome sequencing offers a comprehensive view of cancer genomes, but interpreting the volume of data can be challenging," said Jehee Suh, CEO of Inocras. "Our AI framework aims to streamline this process, making WGS more practical for clinical use by reducing curation workload while maintaining expert oversight."
Unlike approaches based primarily on genomic annotations, Inocras’s new AI framework combines multiple types of evidence that expert curators traditionally assess. The agent can perform a structured review of candidate driver variants using genomic annotations and sequencing metrics and, when additional evidence is needed, can visually inspect sequencing read alignments and retrieve internal knowledge base, expert-curated historical cases.
Inocras is continuing to accumulate additional real-world performance evidence while continuously refining the agent through expert feedback. Human experts retain responsibility for the review and sign-off on all clinical reports.
"Variant curation is becoming an increasingly important rate-limiting step as WGS moves toward broader clinical adoption," said WonChul Lee, CIO and Head of the Innovation Lab at Inocras. "By combining multimodal reasoning, historical expert knowledge, and continuous feedback, our AI framework will be able to automate routine decisions while directing expert attention to the cases that require it most."
Inocras’s AMP presentation, "A Multimodal Agentic AI Framework for Scalable Variant Curation and Clinical Interpretation of Cancer Whole-Genome Sequencing," will be presented by Hansol Park of Inocras’s Data-Centric AI team.
Oral Presentation
Session: Platform Presentations of Selected Informatics Abstracts I
Date: Thursday, November 12, 2026
Time: 2:30–2:45 PM
Presentation: I024 — A Multimodal Agentic AI Framework for Scalable Variant Curation and Clinical Interpretation of Cancer Whole-Genome Sequencing
Location: Room 608–609, Level 6, Arch Building, Seattle Convention Center, 705 Pike St., Seattle, WA
Poster Presentation
Poster Number: I024
Abstract Number: 2465932
Category: Informatics
Poster Display Dates: November 12–14, 2026
Presentation Date: Friday, November 13, 2026
Presentation Time: 9:15–10:15 AM
Location: Expo Hall, Seattle Convention Center
(Press release, Inocras, NOV 9, 2026, View Source [SID1234674516])